Interclean Shanghai

Max Healthcare to acquire 76% stake in Pushpanjali Crosslay for Rs 287 crore

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Max Healthcare Institute Ltd (MHC) has inked agreements to acquire 76 per cent stake in NCR-based Pushpanjali Crosslay Hospital for Rs 287 crore.
"Max Healthcare Institute Ltd. has executed definitive agreements on May 28, 2015 to acquire a controlling stake of 76 per cent in NCR based Pushpanjali Crosslay Hospital (PCH) through a combination of fresh investment and acquisition of shares from existing promoters for an aggregate sum of Rs 287 crore," diversified group Max India said in a filing to BSE.
MHC is an equal joint-venture between Max India and Life Healthcare, South Africa, with both shareholders holding 46 per cent stake each in it, said the filing.
The 340-bed Pushpanjali Crosslay is located along the East Delhi-Ghaziabad-Noida corridor. It has the capacity to expand up to 540 beds and is NABH and NABL accredited. It has been operational since 2010, Max India said.
The hospital had reported revenue of Rs 143 crore at an EBIDTA margin of 14 per cent in FY 2014.
Max India stock was trading at Rs 469.05, down 2.32 per cent, on the BSE.

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »